Abstract-We reported previously that dietary isoflavones modulate arterial blood pressure in vivo and that the daidzein metabolite equol rapidly activates endothelial NO synthase (eNOS) via Akt and extracellular signal-regulated kinase 1/2-dependent signaling. In this study, we report the first evidence in human endothelial cells that acute stimulation of mitochondrial superoxide generation by equol (100 nmol/L) is required for eNOS activation. Scavengers of superoxide (superoxide dismutase and manganese [III] tetrakis [1-methyl-4-pyridyl]porphyrin) abrogated equol stimulated Akt and eNOS phosphorylation, and the mitochondrial complex I inhibitor rotenone inhibited Akt, extracellular signal-regulated kinase 1/2, and eNOS phosphorylation, as well as NO-mediated increases in intracellular cGMP. Equol also induced rapid alterations in F-actin fiber distribution, with depolymerization of F-actin with cytochalasin D abrogating equol-stimulated mitochondrial superoxide generation. Treatment of cells with pertussis toxin or inhibition of GPR30/epidermal growth factor receptor kinase transactivation prevented equol-induced activation of extracellular signal-regulated kinase 1/2 via c-Src, Akt, and eNOS. Moreover, inhibition of epidermal growth factor receptor kinase activation with AG-1478 abrogated equol-stimulated mitochondrial reactive oxygen species generation and subsequent kinase and eNOS activation. Our findings suggest that equol-stimulated mitochondrial reactive oxygen species modulate endothelial redox signaling and NO release involving transactivation of epidermal growth factor receptor kinase and reorganization of the F-actin cytoskeleton. Identification of these novel actions of equol may provide valuable insights for therapeutic strategies to restore endothelial function in cardiovascular disease. Key Words: equol Ⅲ isoflavones Ⅲ endothelium Ⅲ eNOS Ⅲ mitochondria Ⅲ cytoskeleton Ⅲ redox signaling D ietary soy products contain significant amounts of genistein and daidzein, 1,2 which are structurally similar to estrogen, with a preferential affinity for estrogen receptor (ER)-␤. 3 Plasma concentrations of genistein and other isoflavones are as low as 40 nmol/L in humans consuming low-isoflavone diets but can reach Ϸ4 mol/L in Japanese consuming a traditional soybean-rich diet. 4,5 The isoflavone equol is produced by metabolism of daidzein by intestinal gut microflora in only 40% to 50% of individuals, 6 but equol is more bioavailable than either genistein or daidzein and reaches plasma concentrations of Ϸ100 nmol/L in vivo. 5 Cardiovascular benefits of supplementation with genistein and tetrahydrodaidzein have been observed, 7,8 and we reported previously that dietary isoflavones (genistein, daidzein, and equol) can modulate blood pressure in vivo, antioxidant and endothelial NO synthase (eNOS) gene expression, and intracellular glutathione levels in male rats. 9 We further demonstrated that feeding aging male rats an isoflavone-enriched diet improves agonist-mediated endothelium-derived hyperpolarizing factor production in small resistance arteries. 10 A recent study in healthy postmenopausal women established that an isoflavone-enriched, low-fat meal increases endothelium-dependent relaxation in vivo within 5 to 7 hours. 11 Notably, genistein and dehydroequol elicit rapid endothelium-dependent increases in forearm blood flow in vivo, 12, 13 and equol relaxes preconstricted rat aortic rings. 14 In human fetal endothelial cells, equol acutely stimulates endothelial NO release at basal cytosolic Ca 2ϩ levels via activation of extracellular signal-regulated kinase (ERK) 1/2 and protein kinase B (Akt) but independent of classic ER signaling. 14 ERs, aside from their classic function as transcription factors, mediate rapid activation of second messenger systems and intracellular kinases. 15 In addition to GPR30 activation, emerging evidence implicates reactive oxygen species (ROS) as second messengers in the activation of PI3K, ERK1/2, c-Src, and EGFR tyrosine kinase. [25] [26] [27] Although the mitochondrial respiratory chain represents a major source of ROS in the endothelium, 28 to our knowledge there are no reports linking activation of eNOS by equol with increased mitochondrial ROS generation. We hypothesized that modulation of GPR30/EGFR, F-actin cytoskeleton, and mitochondrial ROS generation by equol may account for the acute activation of eNOS.
D
ietary soy products contain significant amounts of genistein and daidzein, 1,2 which are structurally similar to estrogen, with a preferential affinity for estrogen receptor (ER)-␤. 3 Plasma concentrations of genistein and other isoflavones are as low as 40 nmol/L in humans consuming low-isoflavone diets but can reach Ϸ4 mol/L in Japanese consuming a traditional soybean-rich diet. 4, 5 The isoflavone equol is produced by metabolism of daidzein by intestinal gut microflora in only 40% to 50% of individuals, 6 but equol is more bioavailable than either genistein or daidzein and reaches plasma concentrations of Ϸ100 nmol/L in vivo. 5 Cardiovascular benefits of supplementation with genistein and tetrahydrodaidzein have been observed, 7, 8 and we reported previously that dietary isoflavones (genistein, daidzein, and equol) can modulate blood pressure in vivo, antioxidant and endothelial NO synthase (eNOS) gene expression, and intracellular glutathione levels in male rats. 9 We further demonstrated that feeding aging male rats an isoflavone-enriched diet improves agonist-mediated endothelium-derived hyperpolarizing factor production in small resistance arteries. 10 A recent study in healthy postmenopausal women established that an isoflavone-enriched, low-fat meal increases endothelium-dependent relaxation in vivo within 5 to 7 hours. 11 Notably, genistein and dehydroequol elicit rapid endothelium-dependent increases in forearm blood flow in vivo, 12, 13 and equol relaxes preconstricted rat aortic rings. 14 In human fetal endothelial cells, equol acutely stimulates endothelial NO release at basal cytosolic Ca 2ϩ levels via activation of extracellular signal-regulated kinase (ERK) 1/2 and protein kinase B (Akt) but independent of classic ER signaling. 14 ERs, aside from their classic function as transcription factors, mediate rapid activation of second messenger systems and intracellular kinases. 15 Recently, nonclassic membrane-localized ERs have been identified and appear to mediate the rapid actions of 17␤-estradiol on intracellular signaling cascades. 16, 17 The orphan G protein-coupled receptor (GPR30) is a 7-transmembrane spanning G proteincoupled receptor 18, 19 that binds both 17␤-estradiol and genistein. 20 GPR30 has been studied primarily in cancerous cells 21 ; however, vascular cells also express the receptor. 22 Activation of GPR30 induces transactivation of the epidermal growth factor receptor (EGFR) via G␤␥. Once activated, EGFR stimulates ERK1/2 via activation of c-Src and the phosphoinositide 3-kinase (PI3K)/Akt pathway. 23, 24 In addition to GPR30 activation, emerging evidence implicates reactive oxygen species (ROS) as second messengers in the activation of PI3K, ERK1/2, c-Src, and EGFR tyrosine kinase. [25] [26] [27] Although the mitochondrial respiratory chain represents a major source of ROS in the endothelium, 28 to our knowledge there are no reports linking activation of eNOS by equol with increased mitochondrial ROS generation. We hypothesized that modulation of GPR30/EGFR, F-actin cytoskeleton, and mitochondrial ROS generation by equol may account for the acute activation of eNOS.
We report the first evidence that inhibition of mitochondrial ROS abolishes equol-induced activation of Akt, ERK1/2, eNOS phosphorylation, and NO production. Our findings link equol-stimulated mitochondrial ROS generation with EGFR transactivation, because inhibition of EGFR activity inhibits kinase activation and eNOS phosphorylation. Furthermore, depolymerization of the F-actin cytoskeleton, known to interact with both EGFR and mitochondria, abrogates mitochondrial ROS generation. Our study provides a novel link between equol-mediated EGFR activation and downstream signal transduction involving mitochondrial ROS in the activation of eNOS.
Methods
For a more detailed Methods description for immunoblotting, quantitative RT-PCR, and cGMP ELSIA, as well as chemicals and reagents, please see the online Data Supplement at http://hyper.ahajournals.org.
Endothelial Cell Culture
Human umbilical vein endothelial cells (HUVECs) were isolated by collagenase digestion (1 mg/mL) and cultured in low phenol red M199 containing 10% (v/v) FCS, 10% FCS (v/v) newborn calf serum, and 5 mmol/L of L-glutamine and endothelial cell growth factor (20 g/mL). 14 
Chemiluminescence Detection of ROS Generation in Intact Endothelial Cells
Confluent HUVEC monolayers were incubated in low serum (1% FCS) M199 for 4 hours and then preincubated for 30 minutes in Krebs buffer (in mM: NaCl 118.0, KCl 6.0, NaHCO 3 ⅐Ϫ ) dismutase (SOD; 200 U/mL), polyethylene glycol-SOD (PSOD; 50 U/mL), polyethylene glycol-catalase (PCAT; 200 U/mL), manganese (III) tetrakis(1-methyl-4-pyridyl)porphyrin (Mn; 100 mol/L), or rotenone (2 mol/L). Cells were then incubated in Krebs buffer containing lucigenin (5 mol/L) and NADPH (100 mol/L) and challenged with equol (100 nmol/L) or vehicle (0.01% dimethyl sulfoxide [DMSO]) in the absence or presence of inhibitors. Luminescence was immediately recorded in a microplate luminometer (Chameleon V, Hidex) at 37°C after the addition of lucigenin. 29 Maximal luminescence values obtained over a 20-to 40-minute interval (see Figure 1A) were averaged for each treatment condition, and values from 3 to 4 independent cell cultures were expressed as mean light units per milligram of protein.
Mitochondrial ROS Production Measured Using MitoSOX Red Fluorescence
Mitochondrial ROS production was measured using the fluorogenic dye MitoSOX Red, a mitochondrially targeted derivative of hydroethidine. 30 
F-Actin Staining With Rhodamine-Phalloidin
Alterations in F-actin cytoskeletal distribution were visualized in fixed cells stained with rhodamine-phalloidin, as described previously. 31 Cells were treated with control, vehicle (0.01% DMSO), or equol (100 nmol/L) for 20 minutes, fixed, polymerized F-actin fibers stained with rhodamine-phalloidin (500 nmol/L) for 2 hours at room temperature, and nuclei counterstained with Hoechst (10 g/mL Ϫ1 ) for 1 minute. Fluorescence was detected by confocal microscopy with sequential acquisition at wavelengths of 560/625 nm and 375/450 nm used to visualize F-actin and nuclei staining, respectively. In other experiments, cells were pretreated for 30 minutes with cytochalasin D (2.5 mol/L) before cotreating cells for 20 minutes with equol (100 nmol/L) in the continued absence or presence of cytochalasin-D (2.5 mol/L).
Statistical Analysis
Data are expressed as meanϮSEM of measurements in 3 to 5 different HUVEC cultures obtained from different donors, unless stated otherwise. Statistical analyses were performed using a Student 2-tailed t test or 1-way ANOVA followed by Dunnett multiple comparison, with PϽ0.05 considered statistically significant.
Results

Equol Stimulates Intracellular ROS Generation in Intact Endothelial Cells
To investigate whether equol stimulates ROS generation, HUVECs were treated with vehicle (0.01% DMSO) or equol (100 nmol/L), and ROS generation was monitored over a 20-to 40-minute assay using lucigenin chemiluminescence. Equol-stimulated ROS production was abrogated by pretreatment with 200 U/mL of SOD ( Figure 1A) . To confirm the generation of O 2 ⅐Ϫ , cells were preincubated with the cellpermeable H 2 O 2 and O 2 ⅐Ϫ scavenger Mn (100 mol/L), PSOD (50 U/mL), or H 2 O 2 metabolizing enzyme catalase (PCAT; 200 U/mL). Equol-mediated increases in lucigenin chemiluminescence were significantly inhibited by Mn, PSOD, and SOD, whereas PCAT failed to inhibit equolstimulated ROS generation ( Figure 1B ). To determine whether mitochondria were responsible for equol-induced O 2 ⅐Ϫ generation, endothelial cells were pretreated in the absence or presence of the mitochondrial complex I inhibitor rotenone (2 mol/L) and then challenged with equol. Rotenone abrogated equol stimulated O 2 ⅐Ϫ production ( Figure  1C) , and, furthermore, treatment with equol (100 nmol/L) enhanced cellular fluorescence in HUVECs loaded with the mitochondrial-targeted ROS indicator MitoSOX Red ( Figure 1D ).
Effects of O 2 ⅐؊ Scavengers on Equol-Stimulated eNOS, Akt, and ERK1/2 Phosphorylation
We reported previously that equol (100 nmol/L)-stimulated eNOS phosphorylation depends on the activation of Akt and ERK1/2 14 and here provide evidence that equol elicits concentration-and time-dependent increases in eNOS phosphorylation (please see Figure S1 and S2 in the online Data Supplement, available at http://hyper.ahajournals.org). To determine whether inhibition of equol-induced ROS generation affects activation of eNOS and upstream kinases, HUVECs were pretreated with Mn (100 mol/L), PSOD (50 U/mL), or PCAT (200 U/mL) and challenged acutely with equol (100 nmol/L for 2 minutes). Cell lysates were probed for phosphorylated eNOS, phosphorylated Akt, and phosphorylated ERK1/2, and notably Mn and PSOD, but not PCAT, abrogated equol-stimulated phosphorylation of eNOS ( Figure 2A and 2D) and Akt ( Figure 2B and 2E), whereas phosphorylated ERK1/2 was unaffected by these ROS scavengers ( Figure 2C and 2F).
Mitochondrial ROS Generation Is Required for Equol-Induced Kinase and eNOS Phosphorylation
To establish whether mitochondrial O 2 ⅐Ϫ plays a role in equol-stimulated eNOS activation, HUVECs were preincubated with rotenone (2 mol/L for 30 minutes) and then 
Mitochondrial Complex I Inhibition Abolishes eNOS-Dependent cGMP Formation
To confirm that activation of kinases and eNOS by mitochondrial O 2 ⅐Ϫ influences endothelial NO production, effects of rotenone on equol-induced intracellular cGMP accumulation were measured in HUVECs preincubated with an eNOS inhibitor (N G -nitro-L-arginine ester; 100 mol/L) or rotenone (2 mol/L) and then stimulated for 2 minutes with equol (100 nmol/L) in the continued absence or presence of inhibitors. N G -Nitro-L-arginine ester prevented equol-stimulated increases in cGMP levels, confirming intracellular cGMP as a reliable measure NO production ( Figure 3G ). 14 Consistent with rotonene-mediated inhibition of ROS production and phosphorylation of eNOS, Akt, and ERK1/2, rotenone abrogated equol-stimulated cGMP levels.
Mitochondrial ROS Generation Occurs Downstream of EGFR Activation
ROS generation is known to occur downstream of EGFR activation 32 and to also potentiate EGFR transactivation. 33 To establish a relationship between equol-induced EGFR activa- Because F-actin has been shown to modulate mitochondrial ROS production 34, 35 and to potentiate EGFR dimerization by clustering of EGFRs, 36 we hypothesized that F-actin may provide a link between EGFR activation and downstream mitochondrial ROS generation. HUVECs treated with equol (100 nmol/L, 20 minutes) were fixed in 4% paraformaldehyde, polymerized F-actin fibers stained with rhodaminephalloidin (250 nmol/L), nuclei counterstained with Hoechst (10 g/mL), and confocal images of phalloidin with Hoechst staining overlaid. We found that equol induced acute alterations in the arrangement of F-actin, with a thickening of cortical F-actin and the appearance of internal stress fibers ( Figure  5A ). Depolymerization of F-actin after treatment with cytochalasin-D (2.5 mol/L; Figure 5B ) was associated with an inhibition of mitochondrial ROS production ( Figure 5C ), confirming that F-actin may provide a link between EGFR activation and mitochondrial ROS generation.
GPR30-Linked Transactivation of EGFR Mediates ERK1/2, Akt, and eNOS Activation
Estradiol binds GPR30 to stimulate kinase activity, 21 and, because equol is structurally similar to estrogen, 3 we hypothesized a role for GPR30 in Akt and ERK1/2 activation involving G protein-linked EGFR transactivation. Pretreatment of HUVECs with the G-protein inhibitor pertussis toxin (100 ng/mL) or the EGFR kinase inhibitor (AG-1478, 5 mol/L) for 30 minutes blocked equol-stimulated phosphorylation of ERK1/2, Akt, and eNOS ( Figure 6A and 6D and Figure 6B and 6E, respectively). A consistent feature of EGFR transactivation in GPR30 signaling is the recruitment and activation of the protein tyrosine kinase c-Src. 37 Thus, HUVECs were preincubated HUVECs for 30 minutes with a c-Src inhibitor (PP2; 10 mol/L) and then treated acutely for 2 minutes with equol (100 nmol/L). As shown in Figure 6C and 6F, PP2 blocked equol-stimulated eNOS phosphorylation and significantly attenuated ERK1/2 and Akt phosphorylation. Densitometric analysis of phosphorylated Akt and phosphorylated ERK1/2 is summarized in Figure S3 .
Discussion
In humans consuming a soy-rich diet, plasma concentrations of equol range between 1 and 100 nmol/L, 4,5 depending on "equol producer" status. Because equol producers appear to have improved vascular function, it seems likely that the beneficial impact of soy isoflavones on blood pressure and lipid profiles may be influenced by the ability of subjects to metabolize dietary daidzein. 8 Our findings suggest that, in fetal endothelial cells, equol increases mitochondrial ROS, which act as second messengers to induce the rapid stimulation of Akt, ERK1/2, and eNOS activity.
We have obtained novel insights into the cellular mechanisms linking equol-stimulated mitochondrial ROS with activation of eNOS and NO production in endothelial cells. The involvement of ROS in the activation eNOS and upstream kinases was established by observing that inhibition of ROS generation with scavengers of O 2 ⅐Ϫ , but not H 2 O 2 ( Figure  1B) , abrogated equol-stimulated Akt and eNOS phosphorylation (Figure 2A and 2B) . A surprising feature of equolmediated signaling in endothelial cells is that, although this isoflavone has antioxidant properties in endothelial cells, 38 we observed an increase in mitochondrial O 2 ⅐Ϫ production in response to nanomolar concentrations of equol ( Figure 1D ). Although ROS are elevated in cardiovascular and other diseases associated with sustained oxidative stress, under physiological conditions ROS can act as "second messengers" in the regulation of redox-sensitive kinases and transcription factors. [25] [26] [27] [28] Previous studies reported that activation of eNOS by structurally related polyphenols involves ROS-mediated activation of Akt 39, 40 ; however, the intracellular sources and species of ROS were not determined. Mitochondria and NADPH oxidase represent 2 major sources of endothelial ROS generation. 28 Notably, rapid stimulation of ROS generation in endothelial cells by 17␤-estradiol is inhibited by rotenone but unaffected by inhibitors of NADPH oxidase. 35 These studies, together with our present findings, strongly suggest that equol acutely stimulates mitochondrial O 2 ⅐Ϫ generation. Because equol-induced ROS generation was completely inhibited by rotenone and equol-enhanced MitoSOX Red fluorescence, it seems unlikely that Nox2 and Nox4, localized predominantly to the plasma membrane and endoplasmic reticulum, 41,42 modulated eNOS activity. In endothelial cells, NADPH oxidase can also generate extracellular O 2 ⅐Ϫ , which, in turn, may affect intracellular signaling pathways by entering cells through membrane chloride channels. 43 In this context, estrogen downregulates NADPH oxidase subunit expression in endothelial cells after 8 hours, 44 and equol rapidly inhibits NADPH oxidase activity in macrophages. 45 Mitochondria generate ROS via respiratory complexes I and III; however, ROS generation via complex III may play a key role in modulating cytosolic signaling pathways. 46 Inhibition of mitochondrial ROS generation in active cells by rotenone suggests that cells were in state 3. Although elevation of intracellular Ca 2ϩ results in mitochondrial Ca 2ϩ loading and ROS generation, 47 we reported previously that genistein, daidzein, and equol fail to elicit Ca 2ϩ transients in human endothelial cells, 14 suggesting an alternate mechanism for isoflavone-stimulated ROS generation. Our findings suggest that equol-induced mitochondrial ROS and eNOS activation may be mediated by GPR30-linked transactivation of the EGFR. Treatment with pertussis toxin or AG-1478 abolished phosphorylation of eNOS and the upstream kinases Akt and ERK1/2, with ERK1/2 activity dependent on c-Src activation ( Figure 6 ). Similarly, treatment with AG-1478 inhibited mitochondrial ROS production (Figure 4) , indicating that mitochondrial ROS generation occurs downstream of EGFR activation and is unlikely to be attributed to direct binding of equol to the mitochondrial respiratory complexes. EGFR-induced PI3K activation has been suggested previously to mediate mitochondrial ROS production via alterations in mitochondrial ATP-activated potassium channel activity. 32 In contrast, our data indicate that kinase activation occurs downstream of mitochondrial ROS production. Several studies have reported that ROS potentiate EGFR transactivation and, thus, kinase activation. 33, 48 Furthermore, PI3K/ Akt and ERK1/2 kinase pathways are redox sensitive, potentially enabling kinase activation by equol-induced mitochondrial ROS generation.
To our knowledge, we report the first evidence that the isoflavone equol induces rapid alterations in cytoskeletal F-actin distribution ( Figure 5 ). We propose that the mechanism linking EGFR activation and mitochondrial ROS production involves equol-induced alterations in F-actin distribution, because disruption of the cytoskeleton inhibits equol-stimulated mitochondrial ROS generation ( Figure 4B ). It is unlikely that our findings reflect an artifactual disruption of mitochondrial integrity by cytochalasin-D, because previous studies have demonstrated that mitochondria retain their ability to respond to mitochondrial inhibitors, such as antimycin A. 34 Recent findings indicate that F-actin may directly bind to the EGFR 49 and partition EGFR receptors to enhance receptor dimerization, which could, in turn, potentiate mitochondrial ROS and kinase activation. 36 The present study highlights a potential protective role for equol in cardiovascular disease. We propose that equol and other isoflavones evoke mitochondrial O 2 ⅐Ϫ generation in endothelial cells, leading to transactivation of the EGFR; activation of c-Src, ERK1/2, PI3K/Akt, and eNOS; and rapid NO release (please see Figure S4 ).
Perspectives
In view of the importance of the developmental origins of health and disease, 50 our study provides novel insights into the mechanisms by which isoflavones acutely regulate eNOS activity, as well as eNOS mRNA and protein expression (please see Figure S5 ) in fetal endothelial cells. It is worth noting that exposure to dietary soy during fetal development and early life may reduce the susceptibility to cardiovascular disease and obesity in adulthood. 51 By influencing developmental plasticity in utero and in postnatal development, isoflavones may not only alter the expression of genes encoding eNOS 9 but also others associated with metabolism and antioxidant defenses. 52 Thus, based on our previous studies in rodents in vivo 15 and the present findings in fetal endothelial cells, equol and other isoflavones may improve endothelial function and lower blood pressure in the adulthood via fetal programing. 50 Veh 10 Figure S4 . Proposed mechanisms underlying acute activation of eNOS by equol and other dietary isoflavones. Equol and other dietary isoflavones stimulate kinase activation and subsequent eNOS phosphorylation and NO production via mitochondria-derived ROS. Kinase activation may be dependent on GPR30/epidermal growth factor receptor (EGFR) transactivation as previously described. 21, 24 EGFR activation leads to ERK1/2 activation via c-Src and mitochondrial-ROS potentiated Akt activation via PI-3K. Notably, inhibition of mitochondrial ROS generation with rotenone or depolymerization of F-actin abrogates equol stimulated activation of Akt, eNOS and NO production in human endothelial cells. 
